INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 416m ago
HOUSE PTR16m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
SEC FORM 4/Grant or awardVerified data

Elze Christian reported PLX

Director · Protalix BioTherapeutics, Inc. · Protalix BioTherapeutics, Inc. — Restricted Stock Units

Side
A
Value
—
Shares
8,500
Price
—
Executed
Sep 3, 2026
Disclosed
Sep 4, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 3 executedSep 4, 2026 disclosed

PLX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PLX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    NY
    Naos YaronSr. VP & COO
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    56.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BS
    Ben Zvi ShmuelDirector
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    17.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BS
    Ben Zvi ShmuelDirector
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    8,500 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    FE
    Forster EliotDirector
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    17.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    FE
    Forster EliotDirector
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    8,500 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Bashan DrorDirector, PRESIDENT AND CEO
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    320.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Bashan DrorDirector, PRESIDENT AND CEO
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    160.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    EC
    Elze ChristianDirector
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    17.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    NY
    Naos YaronSr. VP & COO
    PLXProtalix BioTherapeutics, Inc.
    Grant or award
    		A—
    112.0K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002075661-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 3, 2026
    Published
    Sep 4, 2026
    Ingested by INSIDER
    Nov 5, 02:18 UTC
    Last re-read
    Nov 5, 02:18 UTC

    Extracted facts

    Filer
    Elze Christian
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Protalix BioTherapeutics, Inc. — Restricted Stock Units
    Ticker
    PLX
    Shares
    8,500
    Price per share
    $0
    Execution date (reported)
    Sep 3, 2026
    Owned after transaction
    8,500 shares
    Days from execution to publication
    1

    What this establishes

    Elze Christian filed this Form 4 reporting a grant or award of PLX on Sep 3, 2026. It became public on Sep 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Elze Christiancik:0002075661
    Issuer
    Protalix BioTherapeutics, Inc.cik:0001006281

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.